학술논문
The Next-Generation Oral Selective Estrogen Receptor Degrader Camizestrant (AZD9833) Suppresses ER+ Breast Cancer Growth and Overcomes Endocrine and CDK4/6 Inhibitor Resistance
Document Type
Article
Author
Lawson, M.; Cureton, N.; Ros, S.; Cheraghchi-Bashi, A.; Urosevic, J.; D’Arcy, S.; Delpuech, O.; Lewis, H.; Trueman, D.; Wali, N.; Williamson, S.C.; Moss, J.; Gagrica, S.; Morentin-Gutierrez, P.; Moss, T.A.; Sutton, D.; Zhang, P.; Critchlow, S.E.; Scott, J.S.; Lindemann, J.P.O.; Barry, S.T.; Morrow, C.J.; Carnevalli, L.S.; DuPont, M.; Gangl, E.T.; Rosen, A.; Fisher, D.I.; Miragaia, R.J.; Maglennon, G.; Polanski, R.; Cairns, J.; Klinowska, T.; Montaudon, E.; Derrien, H.; Marangoni, E.; Sánchez-Guixé, M.; Serra, V.
Source
In: Cancer Research . (Cancer Research, 1 December 2023, 83(23):3989-4004)
Subject
Language
English
ISSN
15387445
00085472
00085472